摘要 |
Use of a human beta defensin having at least 80% identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4 in the manufacture of a medicament for the treatment of an inflammatory disease or disorder selected from the group consisting of osteoarthritis, multiple sclerosis, artherosclerosis, scleroderma (systemic sclerosis), lupus, systemic lupus erythematosus (SLE), (acute) glomerulonephritis, asthma, chronic obstructive pulmonary diseases (COPD), respiratory distress-syndrome (ARDS), vasculitis, uveitis, dermatitis, atopic dermatitis, alopecia, rhinitis (allergica), allergic conjunctivitis, myasthenia gravis, sclerodermitis, sarcoidosis, psoriatic arthritis, psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis,Graves disease, Sjogren's syndrome, and Behçet disease.
|
申请人 |
NOVOZYMES ADENIUM BIOTECH A/S |
发明人 |
KJAER, TANJA MARIA ROSENKILDE;KRUSE, THOMAS;MYGIND, PER HOLSE;BRINCH, KAROLINE SIDELMANN;KJAERULFF, SOEREN;ANDERSEN, BIRGITTE |